Trending Now
Onconova Therapeutics Inc (NASDAQ:ONTX) Inducts Three Patients In The Phase 1...
Onconova Therapeutics Inc (NASDAQ:ONTX) announced three patients' recruitment by its partner - HanX Biopharmaceuticals, in the second cohort of Phase 1 clinical studies of...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Is Loyalty Ventures Inc (LYLT) more than a dead cat bounce
Shares of Loyalty Ventures Inc. (NASDAQ:LYLT) last traded at $0.2709, a gain of over +0.1009$ (+59.35%). More than 194,654,676 shares exchanged hands...
MAKE IT MODERN
LATEST REVIEWS
Proteostasis Therapeutics Inc. (NASDAQ:PTI) Releases In Vitro PTI-129 Results As A...
Proteostasis Therapeutics Inc. (NASDAQ:PTI) has announced results from its in vitro studies to evaluate PTI-129 use in COVID-19 treatment. PTI-129 is the company's preclinical...
MAKE IT MODERN
PERFORMANCE TRAINING
TLC (NASDAQ:TLC) Receives Taiwan and Australian Approval for Commencement of Phase 1 TLC19 Clinical...
TLC (NASDAQ:TLC) has received ethical and scientific approval for its phase I clinical study of TLC19 Hydroxychloroquine Liposome Inhalation suspension for COVID-19 form the...
Compugen Ltd. (NASDAQ: CGEN) Will Give Presentation at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. (NASDAQ: CGEN) announced it would be giving a presentation at the Keystone Symposium on existing the immune tumor microenvironment through...
The European Patent Office Notifies Can-Fite Biopha (NYSEAMERICAN:CANF) Of Its Patent Grant For Namodenoson...
Throughout its many years of operation, Can-Fite Biopha (NYSEAMERICAN:CANF) has been addressing multi-billion dollar markets. Its primary target has been the advancement of cancer...
RECIST Responses with First TC-210 Dose for Mesothelin-expressing Solid Tumors Had Positive Interim Data;...
We all know or have probably heard of someone who has cancer; another monster has taken the world by storm. The most unfortunate thing...
ASH Accepts Kura Oncology Inc.’s (NASDAQ:KURA) Preliminary KOMET-001 Study Data Accepted For Presentation
Kura Oncology Inc. (NASDAQ:KURA) has announced the acceptance for oral presentation of an abstract detailing the preliminary data from its ongoing clinical trial, KOMET-001...
MAKE IT MODERN
